BREAST CANCER

Hope S. Rugo, MD, FASCO, discusses background and key findings from the phase 3 CAPItello-291 trial in breast cancer.

Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

Patritumab deruxtecan treatment yielded efficacy results and was safe for patients with metastatic breast cancer.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

A subgroup analysis from the EMERALD trial reveals that elacestrant prolonged progression-free survival for certain patients with estrogen receptor-positive HER2-negative non-detected shortly after progression on CDK3/6 inhibitors.

Dennis J. Slamon, MD, discusses the key findings from the phase 3 NATALEE trial of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

Findings presented at a press briefing during the 2023 ASCO Annual Meeting revealed that the primary end point was met in the phase 3 NATALEE trial.

Adam Brufsky, MD, PhD, FACP, discusses background and previous clinical data on palbociclib as a treatment option for patients with estrogen receptor-positive, HER2-negative, advanced breast cancer.

In an interview with Targeted Oncology, Andreas Varkaris, MD, PhD, discussed findings from the ReDiscover trial and treating patients with PIK3CA mutations.

The FDA has requested additional information regarding vic-trastuzumab duocarmazine to further evaluate the agent for patients with HER2-positive metastatic breast cancer.

During a Targeted Oncology™ Clinical Case Forum™ event, Terry P. Mamounas, MD, MPH, discussed the treatment landscape for patients with HER2-positive breast cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants what they see as the role of elacestrant for patients with ER+, HER2-negative breast cancer. This is the second of 2 articles based on this event.

Ruta D. Rao, MD, discusses her approach to managing adverse events associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

Charles Geyer, MD, advises his peers on how to manage the grade 3 or higher toxicities and any serious adverse events seen in the clinical trial setting with adjuvant olaparib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.

The safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE161, a potent, selective, small-molecule inhibitor of PARG, is being evaluated in a phase 1 clinical trial for advanced solid tumors.

Closing out his review of HR+/HER2-low metastatic breast cancer management, Kevin Kalinsky, MD, considers unmet needs and ongoing investigation into novel treatment strategies.

Comprehensive insight to the treatment armamentarium for patients with HR+/HER2-low metastatic breast cancer and factors that help inform optimal sequencing.

Expert oncologist Kevin Kalinsky, MD, reviews the diagnosis and management of a 65-year old woman with HR+/HER2-low metastatic breast cancer.

Ruta D. Rao, MD, discussed the trial design and final efficacy results of the ASCENT trial of sacituzumab govitecan in patients with metastatic triple-negative breast cancer.

A phase 2, open-label clinical trial is evaluating treatment with QBS72S in patients with histologically-confirmed breast cancer that has developed brain metastases after a prior cytotoxic chemotherapy regimen.

Sara Hurvitz, MD, discusses updates of the EMERALD trial investigating elacstrant vs the standard of care, including the subgroups of patients who received prior CDK4/6 inhibition for 6, 12, or 18 months.

While results of the PALOMA-2 study did not show a survival benefit for the overall population on the combination of palbociclib and letrozole but did show an overall survival benefit in Black patients on the combination therapy.